Phase III PEMPHIX study showed that Roche ’s Mabthera/Rituxan (rituximab) is superior to standard of care in achieving sustained remission in patients with pemphigus vulgaris

Roche today announced positive topline results from the Roche-sponsored phase III PEMPHIX study, evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news